Control UbiCreERT2 and Glut1fl/flUbiCreERT2 B-ALL cells were, therefore, transferred into immunocompromised hosts that were treated with vehicle or tamoxifen to activate CreERT2, and in vivo and B-ALL growth was assessed with or without Glut1 expression (Figure 6a). The gene discussed is SLC2A1; the disease is acute lymphoblastic leukemia.